Cowen & Co. Sticks to Their Hold Rating for Pacira Pharmaceuticals (PCRX)
Cowen & Co. analyst Boris Peaker maintained a Hold rating on Pacira Pharmaceuticals (PCRX) yesterday and set a price target of $41. The company’s shares closed yesterday at $42.36.
According to TipRanks.com, Peaker is a 3-star analyst with an average return of 2.1% and a 40.1% success rate. Peaker covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics Inc, Stemline Therapeutics Inc, and Mersana Therapeutics Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Pacira Pharmaceuticals with a $68.50 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $55 and a one-year low of $35.07. Currently, Pacira Pharmaceuticals has an average volume of 506.9K.
Based on the recent corporate insider activity of 46 insiders, corporate insider sentiment is negative on the stock. Most recently, in June 2019, David Stack, the CEO & Chairman of PCRX bought 24,000 shares for a total of $73,560.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Pacira Biosciences, Inc. operates as a holding company, which engages in the development, commercialization, and manufacture of pharmaceutical products for use in postsurgical outcomes for acute care practitioners and their patients.